

Company name: TMS Co., Ltd.
Name of representative: Takuro Wakabayashi, Representative
Director and President
(Securities code: 4891; Growth Market)
Inquiries: Go Ito, Director
(Telephone: +81-42-307-7480)

Notice regarding the Changes of Management Structure

TMS Co., Ltd. (the “Company”) hereby announces that it has decided to make following changes of status, responsibilities and title descriptions, effective April 1, 2023.

1. Change of status

Keiji Hasumi, Ph.D, the founder and Chairman of the Company (non-executive board member), will start serving as a full-time board member (Chief Scientific Officer) from April 1, 2023, following his retirement from his position as a full-time professor at Tokyo University of Agriculture and Technology on March 31, 2023.

2. Change of responsibilities and title descriptions

(1) Background

Following the change of Keiji Hasumi, Ph.D., the founder and Chairman of the Company, to a full-time position, the Company has decided to appoint separate responsibilities for the field of research and for the field of development, in order to build a stronger R&D organization.

Takuro Wakabayashi, Representative Director and President of the Company commented as follows. “Since the foundation of the company, Dr. Hasumi has provided strong support to our research team as a professor at Tokyo University of Agriculture and Technology, with which we have joint research partnerships, and as a board member of the company, with his high research capabilities and steadfast beliefs in drug development. In particular, he has led the company’s overall management as the President and Representative Director from 2011 to 2018, a period that was critically important in the development of TMS-007. We are very excited that Dr. Hasumi’s increased involvement in leading the company’s research areas, as a full-time officer, will greatly contribute to the enhancement of the company’s corporate value.”

(2) Detail

| Name | Field in charge | |
|-----------------|----------------------------------|--------------------------|
| | New (Effective April 1, 2023) | Current |
| Keiji Hasumi | Research | - |
| Noriaki Inamura | Development | Research and Development |

3. Change of title descriptions

| Name | New (Effective April 1, 2023) | Current |
|--------------------|--|---------------------------------------|
| Takuro Wakabayashi | Chief Executive Officer | Representative Director and President |
| Keiji Hasumi | Chief Scientific Officer | Scientific Founder, Chairman |
| Go Ito | Chief Financial Officer | Director, CFO |
| Noriaki Inamura | Executive Vice President, Development | Head of R&D |